Sanofi (Ablynx)

Technologiepark 21

9052 Zwijnaarde

BE

Sanofi (Ablynx)

Foundation date

13/07/2001

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Sanofi R&D Belgium based in Ghent is as an end-to-end research and early development Center of Excellence and active in the discovery of NANOBODY® molecules, through the development of drugs up to their clinical proof-of-concept.

NANOBODY® molecules are proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. NANOBODY® technology is the next generation of antibody-derived biologics and have great potential. They are being developed for the treatment of a range of serious and life-threatening human diseases including hematology, inflammation, immune-oncology, oncology and rare diseases.

Upcoming events

Latest news

  • argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia

    19 hours ago

  • Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion

    Wednesday November 22nd 2023

  • argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis

    Thursday November 16th 2023